Skip to main content
Clinical Trials/NCT06250075
NCT06250075
Completed
Not Applicable

Effects of the Use of Probiotics on the Intestinal Microbiota, Clinical-Nutritional and Immunological Status of Patients Gastrectomized for Gastric Cancer: A Randomized Clinical Trial

Universidade Federal do Amazonas1 site in 1 country88 target enrollmentDecember 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Adenocarcinoma
Sponsor
Universidade Federal do Amazonas
Enrollment
88
Locations
1
Primary Endpoint
Modulation of the Intestinal Microbiota
Status
Completed
Last Updated
last year

Overview

Brief Summary

The objective of this randomized controlled, prospective clinical study, composed of 5 groups, G1, G2, G3, G4 and G5 is [Evaluate the intestinal microbiota profile, nutritional, immunological status and inflammatory profile, before and after total or partial removal surgery (gastrectomies) for gastric cancer, in a patient using probiotic supplements.] The main questions it aims to answer are:

  • probiotics are capable of modulating the immune response and microbiota in cancer patients who will undergo surgery
  • surgery itself alters the immunological pattern and microbiota of cancer patients Participants will be divided into groups for evaluation and the G1 intervention group will take probiotic capsules.

The researchers will compare groups G1, G2 with G3 (negative control group) to see if there are differences between using probiotics or not, in controlling the immune response and if there are significant changes in their intestinal microbiota. Groups G4 and G5 will also be compared, where in these we will only measure the power of the use of probiotics in reducing surgical complications in the postoperative period.

Registry
clinicaltrials.gov
Start Date
December 12, 2020
End Date
April 26, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Universidade Federal do Amazonas
Responsible Party
Principal Investigator
Principal Investigator

Abner Souza Paz, RD

Principal Investigator

Universidade Federal do Amazonas

Eligibility Criteria

Inclusion Criteria

  • Patients with indication for total or partial gastrectomy;
  • Ages from 18 years old.

Exclusion Criteria

  • Palliative patients
  • Use of probiotics and prebiotics in the last 15 days;
  • Patients who are unable to complete all monitoring steps;
  • AIDS patients;
  • Diabetic patients;
  • Pregnant patients;
  • Patients with Autoimmune Diseases;
  • Patients with Liver Diseases;
  • Patients with Kidney Disease;
  • Patients with Inflammatory Bowel Diseases.

Outcomes

Primary Outcomes

Modulation of the Intestinal Microbiota

Time Frame: twelve months

The use of probiotics positively interfered in maintaining a change in the pre-surgical microbial profile, in relation to the post-surgical one.

Modulation of the Immune Response

Time Frame: twelve months

We will measure (measure the concentration) of inflammatory cytokines through flow cytometry, and then observe whether the intervention interferes negatively or positively in the inflammatory pattern.

The use of probiotics can modify the incidence of postoperative complications

Time Frame: twelve months

During surgery, many inflammatory factors can interfere with the appearance of postoperative complications. We assume that the use of probiotics can beneficially modulate surgical complications.

Secondary Outcomes

  • Modulation of nutritional parameters with the use of probiotics-weight and height(twelve months)
  • Modulation of nutritional parameters using probiotics-phase angle(twelve months)

Study Sites (1)

Loading locations...

Similar Trials